Following non-approvable Complete Response Letters (CRL) from the FDA the companies in a three-way horse race for obesity treatments have been moving ahead with remedial plans for eventual approval. Based on information around recent discussions with

read more: Qnexa Moves Into Lead in Three-Way Horse Race on Obesity Drug Approval